Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017, Article ID 2321052, 3 pages
https://doi.org/10.1155/2017/2321052
Case Report

Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma

1Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
2Division of Medical Oncology, University of Kansas Medical Center, Kansas City, KS, USA

Correspondence should be addressed to Anup Kasi Loknath Kumar; moc.liamg@codpuna

Received 13 March 2017; Revised 5 June 2017; Accepted 15 June 2017; Published 24 July 2017

Academic Editor: Jose I. Mayordomo

Copyright © 2017 Anusha Vittal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar
  2. M. Peeters, G. Kafatos, A. Taylor et al., “Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials,” European Journal of Cancer, vol. 51, no. 13, article 9489, pp. 1704–1713, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. P. T. C. Wan, M. J. Garnett, S. M. Roe et al., “Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF,” Cell, vol. 116, no. 6, pp. 855–867, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Lièvre, J. B. Bachet, D. le Corre et al., “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer,” Cancer Research, vol. 66, no. 8, pp. 3992–3995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Y. Douillard, K. S. Oliner, and S. Siena, “Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer,” The New England Journal of Medicine, vol. 369, no. 11, pp. 1023–1034, 2013. View at Publisher · View at Google Scholar
  6. A. Italiano, I. Hostein, I. Soubeyran et al., “KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications,” Annals of Surgical Oncology, vol. 17, no. 5, pp. 1429–1434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. S. Schwartzberg, F. Rivera, M. Karthaus et al., “PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 32, no. 21, pp. 2240–2247, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Y. Douillard, S. Siena, J. Cassidy et al., “Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer,” Annals of Oncology, vol. 25, no. 7, pp. 1346–1355, 2014. View at Publisher · View at Google Scholar
  9. E. Van Cutsem, H.-J. Lenz, C.-H. Köhne et al., “Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer,” Journal of Clinical Oncology, vol. 33, no. 7, pp. 692–700, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. I. H. Sahin, S. M. A. Kazmi, J. T. Yorio, N. A. Bhadkamkar, B. K. Kee, and C.-P. R. Garrett, “Rare though not mutually exclusive: a report of three cases of concomitant kras and braf mutation and a review of the literatuer,” Journal of Cancer, vol. 4, no. 4, pp. 320–322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Seth, S. Crook, S. Ibrahem, W. Fadhil, D. Jackson, and M. Ilyas, “Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer,” Gut, vol. 58, no. 9, pp. 1234–1241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. T. S. Maughan, R. A. Adams, C. G. Smith et al., “Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial,” The Lancet, vol. 377, no. 9783, pp. 2103–2114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Capalbo, P. Marchetti, A. Coppa et al., “Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report,” Cancer Biology and Therapy, vol. 15, no. 7, pp. 826–831, 2014. View at Publisher · View at Google Scholar · View at Scopus